Glaukos Corp.

Glaukos Corp.

Glaukos Corp.

Overview
Date Founded

1998

Headquarters

26051 Merit Circle,Suite 103,Laguna Hills, CA 92653

Type of Company

Public

Employees (Worldwide)

437

Industries

Medical Products & Equipment
Medical Support Services
Hospitals & Patient Services

Company Description

Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Contact Data
Trying to get in touch with decision makers at Glaukos Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer & Senior Vice President-Corporate Development

Chief Operating Officer

Secretary, Senior Vice President & General Counsel

Chief Medical Officer

Senior Vice President-Human Resources

Senior Vice President, New Technologies

Senior Vice President, Regulatory Affairs

Senior Vice President, Corporate Strategy & Business Development

Vice President-Research & Development

Board of Directors

Co-Founder at Versant Venture Management LLC

Corporate Vice President, General Counsel at Edwards Lifesciences Corp.

Managing Member at RWI Ventures Management Co. LLC

Chairman & Chief Executive Officer at Helix

President at BioTrove, Inc.

Managing Director at InterWest Partners, LLC

President & Chief Executive Officer at Glaukos Corp.

Paths to Glaukos Corp.
Potential Connections via
Relationship Science
You
Glaukos Corp.
Owners & Shareholders
Details Hidden

WBIM is an active investment manager that utilizes a variety of methods and strategies to make investment decisions and recommendations. The firm employs both fundamental and technical research methods when evaluating investment opportunities. They use various resources such as financial newspapers, magazines and websites; corporate data; ratings services; third party research; SEC filings; company press releases; and proprietary research. WBIM manages primarily US international and global equity portfolios and US fixed income portfolios for their clients. Their investment strategies include: US Growth; US Value; International and Global Equity; Chinese Securities; US Fixed Income, Hedge Fund Strategies, Dynamic Allocation; International Systematic Research; and Directional Multi-Alternative Strategies.

Details Hidden

Our firm was founded to help small investors build significant capital over time. Since we believe in owning as many promising stocks as possible, we generally buy on margin.* Borrowing to invest can force liquidations if the market collapses, so we try to balance this exposure by selling short. This ability to seek investments both up and downstream is rarely available to smaller investors. We, however, view it as an effective tool that doubles our clients' dollars at work (it also doubles our commissions), while moderately reducing their exposure to abrupt swings in the market. Our approach is not for the short-term investor. Clients must be able and willing to accept risks. Accounts will experience sharp fluctuations month to month, year to year. It takes a strong stomach to invest with us. Clients entrust decision making for their accounts to us: we buy and sell without asking our clients to authorize in advance each transaction. We are paid commissions for our work

Details Hidden

FGIM primarily provides advice with respect to equity investment strategies; however, they do not recommend a particular type of security. The firm is a multi strategy investor that manages portfolios of equity and fixed-income investments for institutional and private clients. Their strategies include core international/emerging market equities; international equity; international small- and mid-cap equity; balanced/asset allocation; managed risk and the Kaufmann Accounts. The Kauffman strategy invests in small, mid or large cap stocks, utilizing a fundamental bottom-up process seeking growth companies and may invest in less developed or emerging markets.

Recent Transactions
Details Hidden

Glaukos Corp. issued Common Stock

Details Hidden

Glaukos Corp. raised money in a private placement transaction

Details Hidden

Glaukos Corp. raised money in a private placement transaction

Transaction Advisors
Escrow Agent

Advised onGlaukos Corp. issued Common Stock

Underwriter

Advised onGlaukos Corp. issued Common Stock

Underwriter

Advised onGlaukos Corp. issued Common Stock

Advisors & Consultants
Advisor

Former Chief Financial Officer & Secretary at DOSE Medical Corp.

Advisor

Senior Vice President-Strategy at Medtronic Plc

Key Stats and Financials As of 2018
Market Capitalization
$2.52B
Total Enterprise Value
$1.84B
Earnings Per Share
$-0.37
Revenue
$181M
Net Profit
$-13M
EBITDA
$-6.74M
EBITDAMargin
-3.72%
Total Debt
$0
Total Equity
$174M
Enterprise Value Sales
10.17x
TEVNet Income
-142.33x
Debt TEV
0x
Non-Profit Donations & Grants
$10K - $25K
2016
$5,000 - $10K
2015
$10K - $25K
2014
Investors
Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Details Hidden

MeriTech Capital Partners provides late-stage venture capital to information technology and medical technology companies including companies in the communications, software and services, enterprise infrastructure, semiconductors and components, consumer Internet and media and medical devices and services industries. The firm invests globally.

Details Hidden

Domain Associates invests exclusively in emerging life sciences companies. The firm focuses on pharmaceuticals, specialty pharmaceuticals and medical devices and they are also interested in biomaterials, bioinstrumentation and diagnostics. They prefer to be part of the first institutional financing round of a company. They look for companies with outstanding technology addressing unmet needs in very large markets led by exceptional management. Once invested, Domain takes an active role in guiding the growth of the company. They take a seat on the Board of Directors in the vast majority of cases. Most of their investments are in private companies, but they also invest in small-cap public healthcare companies that are implementing a new corporate strategy.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Allergan Plc Pharmaceuticals - Dublin, DU

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Alcon, Inc. Medical Products & Equipment

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through Surgical and Vision Care segments. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Hünenberg, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Glaukos Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Glaukos Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Glaukos Corp..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/glaukos-corp-158410
  • https://relationshipscience.com/organization/glaukos-corp-158410